Public health and WHOAn Expensive Prescription Drug? The Truth About Conferences Funded by Companies!
What do Natural Therapy Specialists write?
Pharmaceutical companies fund conferences where lectures about new drugs predominate, rather than lectures about new treatment methods.
Medical schools are said to depend on money from pharmaceutical companies, which, according to the author, makes it difficult to use methods outside the industry.
The author calls doctors who act at the pharmaceutical industry's direction its sales agents.
The author claims that doctors are made to choose between independent treatment and following orders linked to the interests of industry.
The author claims that, in exchange for banning effective methods, doctors are instructed to use expensive drugs with little effectiveness.
The STOP NOP Association says that industry influences, among other things, the training of health care workers and medical practice.
According to the STOP NOP Association, industry interference may exaggerate the benefits of drugs, downplay their possible harms, and influence practice and guidelines.
The STOP NOP Association writes that industry directly influences decisions made by health care workers.
Jerzy Jaśkowski claims that doctors have been manipulated into selling harmful products while believing that they are helping patients.
Jerzy Jaśkowski accuses cardiologists of providing the pharmaceutical industry with chronically ill patients.
What does scientific research from PubMed · Europe PMC say?
We selected 10 studies with the best, positive results. This is a selection, not a full review of all research.
Total number of studies on this topic in PubMed: 4 108.
Aim of the study: Controversy exists over the fact that physicians have regular contact with the pharmaceutical industry and its sales representatives, who spend a large sum of money each year promoting to them by way of gifts, free meals, travel subsidies, sponsored teachings, and symposia.
Results: The present extent of physician-industry interactions appears to affect prescribing and professional behavior and should be further addressed at the level of policy and education.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Pharmaceutical companies spend large amounts of money promoting their products to physicians. There is evidence that physicians' interactions with pharmaceutical companies negatively affect their prescribing patterns. The objective of this study was to systematically review the extent of the relationship between physicians and pharmaceutical companies in low- and middle-income countries (LMICs).
Results: We included 11 eligible studies (7 quantitative and 4 qualitative). Quantitative studies found that pharmaceutical company representatives visited at least 90% of physicians. Printed material, stationery items and drug samples were the most frequently received gifts. Two of the studies assessing direct payment found percentages of 16 and 5%, respectively. Findings of qualitative studies were consistent with those of quantitative studies. In addition, they revealed an increasing tendency for pharmaceutical companies to provide expensive personal gifts, sponsor social events and offer cash as inducements to physicians based on their demands. They also identified building personal relationships, creating a sense of indebtedness and emotional blackmailing as commonly used techniques to influence physicians. A relatively high percentage of physicians in LMICs interact with pharmaceutical companies.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: To evaluate the association between industry payments to physicians related to poly (ADP-ribose) polymerase inhibitors (PARPis) and physicians' prescribing behaviors for PARPis.
Results: Of the 1686 eligible physician prescribers, 68.7% received one or more non-research payments related to any of the three PARPis from the manufacturers between 2017 and 2021. Median annual payments per physician were $57 for olaparib, $39 for rucaparib, and $62 for niraparib. Receipt of payments for each PARPi was associated with higher odds of prescribing olaparib (odds ratio [OR]: 1.30 [95% CI: 1.14-1.48], p < 0.001), rucaparib (OR: 2.07 [95% CI: 1.58-2.72], p < 0.001), and niraparib (OR: 1.49 [95% CI: 1.22-1.81], p < 0.001). Dose-response effects were observed between the number of annual payments and the number of prescriptions and/or Medicare expenditures for olaparib and rucaparib. Non-research payments to physician prescribers of PARP inhibitors from the manufacturers were significantly associated with increased prescriptions and Medicare expenditures for olaparib and rucaparib in the United States.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: The pharmaceutical industry spends billions of dollars every year for marketing its products to US health care providers. This study investigates the association between industry marketing payments and physicians' prescription in New York and Massachusetts, and examines the effect of the Massachusetts payment restriction policy on this association in comparison with the New York State that has no payment restriction policy.
Results: Moreover, FE and FD models show that compared to NYS physicians, the association of industry payments with days' supply and costs of Medicare Part D prescriptions was (0.01%-0.02%) smaller for MA physicians. Because of the smaller sample size and lower power, the LFD model did not detect a significant difference between the NYS and MA providers. The findings of this study provide additional evidence that industry payments are associated with increases in the volume and cost of Medicare prescriptions. Moreover, these findings provide preliminary evidence that payment restriction policies negatively moderate this association, which calls for further research.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Payments to physicians by the pharmaceutical industry are common, but recent evidence shows that these payments influence physician prescribing behavior in the form of increased prescription of brand-name drugs, expensive and low-cost drugs, increased prescription of payer company drugs, etc. Considering that these payments increase drug costs for patients and health systems, there is a public interest in controlling them.
Results: In the search, 579 articles were retrieved, and 44 articles were found suitable for the final analysis. Twenty-nine interventions and strategies were identified, and based on these; Five policy options were identified: prohibition, restriction, physician self-regulation, voluntary industry disclosure, and mandatory industry disclosure. The proposed policies in our study include advantages, challenges, and implementation considerations based on up-to-date evidence that can help policymakers use them to manage COI in physician-pharmaceutical industry interactions in Iran's health system. A combination of measures seems to help manage COI: firstly, using self-regulating physicians and industry to institutionalize transparency, and in the next step, implementing mandatory industry disclosure policies and establishing restrictions on some financial interactions.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Due to sanitary restrictions secondary to the COVID-19 pandemic, various interactions between the pharmaceutical industry and physicians have changed. One of them has been the method for promoting medicinal products through academic meetings around diseases of financial interest.
Results: One of them has been the method for promoting medicinal products through academic meetings around diseases of financial interest. A recent modality has been unilateral promotion by the pharmaceutical industry through academic events with the invitation of so-called "experts" for the promotion of a specific drug. These meetings are often biased not towards optimal care of a disease, but rather towards commercial promotion of a specific drug, which may or may not be the best option, without considering associated therapeutic alternatives. The Committee of Ethics and Transparency in the Physician-Industry Relationship, of the National Academy of Medicine, analyzes this new circumstance and proposes some considerations to the medical community.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: The Centers for Medicare & Medicaid Services (CMS) Open Payments public database, resulting from the Physician Payments Sunshine Act of 2010, was designed to increase transparency of physicians' financial relationships with pharmaceutical manufacturers. We compared physician-reported conflict-of-interest (COI) disclosures in journal articles with this database to determine any discrepancies in physician-reported disclosures.
Results: We reviewed 3,465 authorship positions (1,932 unique authors) in 1,770 articles. Within this sample, 7.1% of authorships had a recorded undisclosed COI (disclosure discrepancy), and 13.2% of articles had first and/or last authors with a disclosure discrepancy. Additionally, we saw a great variation in the percentage of authorships with disclosure discrepancies among the journals (JBJS, 2.3%; JOA, 3.6%; and FAI, 23.7%). Discrepancies exist between payment disclosures made by authors and those published in the CMS Open Payments database. Although the percentage of articles with these discrepancies varies widely among the journals that were analyzed in this study, no trend was found when analyzing the number of discrepancies over the 3-year period.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Interactions between cancer physicians and the pharmaceutical industry may create conflicts of interest that can adversely affect patient care. We aimed to survey cancer physicians regarding their attitudes toward and interactions with industry.
Results: There were 116 responses (94 complete). Almost half (n = 53 of 115, 46.1%) felt that there was a positive relationship between cancer physicians and industry. Most (n = 79 of 104, 76.0%) interacted with industry at least once a month, and 67.7% (n = 63 of 93) had received nonresearch payments from industry previously, with a median value of 2,000 Australian dollars over 1 year. Most respondents believed that interactions could influence prescribing while simultaneously denying influence on their own prescribing (n = 66 of 94, 70.2%). Those who judged general sales representative interactions (odds ratio [OR] 9.37 [95% CI, 1.05 to 83.41], P = .045) or clinician sponsorship (OR 3.22 [95% CI, 1.01 to 10.30], P = .049) to be more acceptable also met with sales representatives more frequently.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Canada is a laggard when it comes to transparency of transfers of value between the pharmaceutical industry and physicians and patient groups. In most high-income countries, transparency is mandated by the government or required for membership in industry associations.
Results: In most high-income countries, transparency is mandated by the government or required for membership in industry associations. Aside from one attempt by a previous Ontario Liberal government, provincial and federal governments have steered clear of this issue, and the role of Innovative Medicines Canada has been minimal. There is evidence showing that the receipt of payments by physicians and patient groups is associated with actions favourable to the pharmaceutical industry. Companies should have to disclose the payments that they make.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Conflicts of interest (COI) between physicians and for-profit companies have existed for centuries, but the last decade has dramatically increased their visibility through the Centers for Medicare and Medicaid Services' Open Payments database.
Results: The authors review the evidence linking industry interactions during medical training to favorable views of pharmaceutical marketing, greater propensity for continued industry engagement, and increased prescribing of promoted drugs and devices. The authors argue that medical schools and their governing bodies must implement and enforce meaningful COI policies, meeting at minimum the Association of American Medical Colleges' existing recommendations. The authors further recommend that the Liaison Committee on Medical Education require adherence to these policies for annual accreditation, that research curricula address the influence of funding sources on study design, and that the Open Payments database be integrated into medical training as a transparency tool. Strengthening COI education and policy is essential to ensure that the next generation of physicians learns in environments where patient-centered, evidence-based medicine guides decision-making.
“Not stated” does not mean nobody paid — the database does not always record it.
What do orthomolecular medicine doctors write?
Sources (18)
- Jerzy Zięba — Nasze zdrowie w naszych rękach
- Andrzej Frydrychowski — Prawo do zawodu
- Andrzej Frydrychowski — Czy dzisiejsi lekarze są podmiotami ustaw medycznych, czy wykonawcami algorytmów – administratorami interesów wielkiego przemysłu?
- Stowarzyszenie STOP NOP — Przemysł farmaceutyczny fałszuje korzyści i szkodliwość swoich produktów wpływając na system ochrony zdrowia – Ogólnopolskie Stowarzyszenie Wiedzy o Szczepieniach "STOP NOP"
- Jerzy Jaśkowski — Czego nie wiemy o statynach?
- Physicians and the pharmaceutical industry: is a gift ever just a gift? · JAMA 2000
- Extent of physician-pharmaceutical industry interactions in low- and middle-income countries: a systematic review. · Eur J Public Health 2018
- Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States. · Gynecol Oncol 2024
- Industry payments and physicians prescriptions: Effect of a payment restriction policy. · Soc Sci Med 2021
- Interaction between physicians and the pharmaceutical industry: A scoping review for developing a policy brief. · Front Public Health 2022
- New interaction modalities between the pharmaceutical industry and physicians. · Gac Med Mex 2022
- Disclosures Undisclosed. · J Bone Joint Surg Am 2019
- Australian Cancer Physicians and the Pharmaceutical Industry: A Survey of Attitudes and Interactions. · JCO Oncol Pract 2022
- Lack of Transparency in Pharmaceutical Industry Payments to Canadian Physicians and Patient Groups. · Healthc Policy 2026
- Industry Exposure in Medical Training: The Case for a Conflict-Free Learning Environment. · J Law Med Ethics 2026
- Orthomolecular Medicine News Service — Unveiling the Corporate Agenda Behind the Global Plant-Based Food Movement
- Orthomolecular Medicine News Service — The Mismanagement of ASCVD: A Call for Root Cause Solutions Beyond Cholesterol
- Orthomolecular Medicine News Service — Truth in Pharmaceutical Advertising
Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.